Financials in USD. Standardized financial statements.
A compact view of how Coherus Oncology, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $42.17M | $266.96M | $257.24M | $211.04M | $326.55M | $475.82M | $356.07M | $1.56M | $1.56M | $190.11M |
| Revenue Growth? | -84.2% | +3.8% | +21.9% | -35.4% | -31.4% | +33.6% | +22783.7% | 0.0% | -99.2% | 0.0% |
| Cost of Revenue? | $17.74M | $117.55M | $158.99M | $70.08M | $57.59M | $37.67M | $17.08M | $3.23M | $160.53M | $254.44M |
| Gross Profit? | $24.43M | $149.41M | $98.25M | $140.96M | $268.96M | $438.16M | $338.99M | -$1.68M | -$158.97M | -$64.33M |
| Gross Margin? | +57.9% | +56.0% | +38.2% | +66.8% | +82.4% | +92.1% | +95.2% | -107.9% | -10216.9% | -33.8% |
| Operating Expenses? | $203.97M | $261.07M | $301.45M | $397.84M | $532.82M | $281.84M | $231.22M | $204.42M | $233.69M | $306.04M |
| Operating Income? | -$179.53M | -$111.67M | -$203.20M | -$256.88M | -$263.86M | $156.32M | $107.77M | -$204.42M | -$232.14M | -$115.93M |
| EBITDA? | -$175.61M | $60.94M | -$193.94M | -$255.58M | -$260.69M | $161.84M | $111.03M | -$204.42M | -$225.34M | -$116.81M |
| Income Before Tax | -$183.12M | $28.51M | -$238.27M | -$291.75M | -$287.10M | $135.71M | $92.78M | -$209.41M | -$238.29M | -$127.79M |
| Income Tax Expense | $0 | $0 | -$380,000 | $0 | $0 | $3.46M | $2.94M | $0 | $0 | $656,000 |
| Net Income? | -$170.29M | $28.51M | -$237.89M | -$291.75M | -$287.10M | $132.24M | $89.83M | -$209.34M | -$238.17M | -$127.34M |
| EPS? | $-1.45 | $0.25 | $-2.53 | $-3.76 | $-3.81 | $1.85 | $1.29 | $-3.22 | $-4.48 | $-3.04 |
| Diluted EPS? | $-1.45 | $0.25 | $-2.53 | $-3.76 | $-3.81 | $1.62 | $1.23 | $-3.22 | $-4.48 | $-3.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality